Schoof DD - Search Results

1

The influence of angiogenesis inhibitor AGM-1470 on immune system status and tumor growth in vitro.

Schoof DD, Obando JA, Cusack JC Jr, Goedegebuure PS, Brem H, Eberlein TJ. Schoof DD, et al. Int J Cancer. 1993 Oct 21;55(4):630-5. doi: 10.1002/ijc.2910550419. Int J Cancer. 1993. PMID: 7691763

2

The systemic complement activation caused by interleukin-2/lymphokine-activated killer-cell therapy of cancer causes minimal systemic neutrophil activation.

Moore FD Jr, Schoof DD, Rodrick M, Eberlein TJ. Moore FD Jr, et al. Among authors: schoof dd. Int J Cancer. 1991 Oct 21;49(4):504-8. doi: 10.1002/ijc.2910490405. Int J Cancer. 1991. PMID: 1917149

3

Solid-phase anti-CD3 antibody activation of murine tumor-infiltrating lymphocytes.

Massaro AF, Schoof DD, Rubinstein A, Zuber M, Leonard-Vidal FJ, Eberlein TJ. Massaro AF, et al. Among authors: schoof dd. Cancer Res. 1990 May 1;50(9):2587-92. Cancer Res. 1990. PMID: 2139356

4

Human tumor-infiltrating lymphocyte (TIL) cytotoxicity facilitated by anti-T-cell receptor antibody.

Schoof DD, Jung SE, Eberlein TJ. Schoof DD, et al. Int J Cancer. 1989 Aug 15;44(2):219-24. doi: 10.1002/ijc.2910440205. Int J Cancer. 1989. PMID: 2503456

5

Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells.

Schoof DD, Gramolini BA, Davidson DL, Massaro AF, Wilson RE, Eberlein TJ. Schoof DD, et al. Cancer Res. 1988 Sep 1;48(17):5007-10. Cancer Res. 1988. PMID: 3261630

6

The biological effects of immunosuppression on cellular immunotherapy.

Schoof DD, Massaro AF, Obando JA, Kusack JC Jr, Eberlein TJ. Schoof DD, et al. Surg Oncol. 1992 Feb;1(1):27-35. doi: 10.1016/0960-7404(92)90053-n. Surg Oncol. 1992. PMID: 1341232

7

Secondary cytokine production by lymphoid cells used in cellular immunotherapy.

Schoof DD, Hunt P, Obando JA, Cusack JC Jr, Andrews V, Terashima Y, Eberlein TJ. Schoof DD, et al. Surg Oncol. 1992 Apr;1(2):163-72. doi: 10.1016/0960-7404(92)90030-o. Surg Oncol. 1992. PMID: 1341247

8

Approaches to immunotherapy of cancer: characterization of lymphokines as second signals for cytotoxic T-cell generation.

Bertagnolli MM, Herrmann SH, Pinto VM, Schoof DD, Eberlein TJ. Bertagnolli MM, et al. Among authors: schoof dd. Surgery. 1991 Sep;110(3):459-68. Surgery. 1991. PMID: 1887370 Review.

9

The role of interleukin-2 in cancer immunotherapy.

Eberlein TJ, Schoof DD. Eberlein TJ, et al. Among authors: schoof dd. Compr Ther. 1991 Jan;17(1):49-56. Compr Ther. 1991. PMID: 2001612

10

Activation of human tumor-infiltrating lymphocytes by monoclonal antibodies directed to the CD3 complex.

Schoof DD, Selleck CM, Massaro AF, Jung SE, Eberlein TJ. Schoof DD, et al. Cancer Res. 1990 Feb 15;50(4):1138-43. Cancer Res. 1990. PMID: 2137027

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

33 results

Search Page

Filters